Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma

Ding,Chuanjin; Zhang,Qicheng; Chen,Yan; Zhang,Xiaobo; Wu,Pei; Zhang,Zhenxin

doi:10.3892/or.2017.5761

Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma

Authors:
- Chuanjin Ding
- Qicheng Zhang
- Yan Chen
- Xiaobo Zhang
- Pei Wu
- Zhenxin Zhang
View Affiliations

Affiliations: Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/or.2017.5761
Pages: 866-874
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to determine the effect of A disintegrin and metalloprotease 10 (ADAM10) protein expression on the progression, migration and prognosis of hypopharyngeal squamous cell carcinoma (HSCC). Immunohistochemistry and western blot analysis were performed to detect ADAM10 expression in human HSCC specimens. Cell Counting Kit-8 (CCK-8) assay, flow cytometry analysis and wound-healing assay were employed to investigate the effects of ADAM10 knockdown (ADAM10-RNAi) on major oncogenic properties of FaDu cells. We detected that ADAM10 was overexpressed in HSCC specimens and its expression level was associated with differentiation (p<0.001), tumor size (p=0.019), lymph node metastasis (p=0.001), clinical stage (p<0.001), proliferation marker Ki-67 expression (P=0.001) and overall survival (p<0.046). ADAM10-RNAi in FaDu cells resulted in the inhibition of proliferation and the decrease in migration. Moreover, mechanistic experiments revealed that ADAM10-RNAi resulted in an increase in E-cadherin and a decrease in N-cadherin and vimentin expression. Our study implies that high expression of ADAM10 promotes the proliferation and migration of HSCC. These findings may help to provide a method for treatment of HSCC.

View Figures

View References

1	Ligier K, Belot A, Launoy G, Velten M, Bossard N, Iwaz J, Righini CA, Delafosse P and Guizard AV: network Francim: Descriptive epidemiology of upper aerodigestive tract cancers in France: Incidence over 1980–2005 and projection to 2010. Oral Oncol. 47:302–307. 2011. View Article : Google Scholar : PubMed/NCBI
2	Takes RP, Strojan P, Silver CE, Bradley PJ Jr, Haigentz M Jr, Wolf GT, Shaha AR, Hartl DM, Olofsson J, Langendijk JA, et al: International Head and Neck Scientific Group: Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery. Head Neck. 34:270–281. 2012. View Article : Google Scholar : PubMed/NCBI
3	Hoffman HT, Karnell LH, Shah JP, Ariyan S, Brown GS, Fee WE, Glass AG, Goepfert H, Ossoff RH and Fremgen AM: Hypopharyngeal cancer patient care evaluation. Laryngoscope. 107:1005–1017. 1997. View Article : Google Scholar : PubMed/NCBI
4	Godballe C, Jørgensen K, Hansen O and Bastholt L: Hypopharyngeal cancer: Results of treatment based on radiation therapy and salvage surgery. Laryngoscope. 112:834–838. 2002. View Article : Google Scholar : PubMed/NCBI
5	Lee MS, Ho HC, Hsiao SH, Hwang JH, Lee CC and Hung SK: Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Otolaryngol. 128:103–109. 2008. View Article : Google Scholar : PubMed/NCBI
6	Chung EJ, Lee SH, Baek SH, Park IS, Cho SJ and Rho YS: Pattern of cervical lymph node metastasis in medial wall pyriform sinus carcinoma. Laryngoscope. 124:882–887. 2014. View Article : Google Scholar : PubMed/NCBI
7	Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
8	Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci. 98:621–628. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lu X, Lu D, Scully M and Kakkar V: ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
10	Murphy G: The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008. View Article : Google Scholar : PubMed/NCBI
11	Klein T and Bischoff R: Active metalloproteases of the A disintegrin and metalloprotease (ADAM) family: Biological function and structure. J Proteome Res. 10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
12	Saftig P and Lichtenthaler SF: The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. Prog Neurobiol. 135:1–20. 2015. View Article : Google Scholar : PubMed/NCBI
13	Vincent B: Regulation of the α-secretase ADAM10 at transcriptional, translational and post-translational levels. Brain Res Bull. 126:154–169. 2016. View Article : Google Scholar : PubMed/NCBI
14	Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M and Nikolov DB: Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell. 123:291–304. 2005. View Article : Google Scholar : PubMed/NCBI
15	Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D and Saftig P: ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J. 24:742–752. 2005. View Article : Google Scholar : PubMed/NCBI
16	Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D and Saftig P: ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA. 102:9182–9187. 2005. View Article : Google Scholar : PubMed/NCBI
17	Moss ML, Stoeck A, Yan W and Dempsey PJ: ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol. 9:2–8. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Liu S, Liu K, Wang Y, Ji B, Zhang X and Liu Y: A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
19	You B, Shan Y, Shi S, Li X and You Y: Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma. Cancer Sci. 106:1506–1514. 2015. View Article : Google Scholar : PubMed/NCBI
20	Guo J, He L, Yuan P, Wang P, Lu Y, Tong F, Wang Y, Yin Y, Tian J and Sun J: ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway. Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
21	Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and Tao HQ: ADAM 10 is associated with gastric cancer progression and prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
22	Fu L, Liu N, Han Y, Xie C, Li Q and Wang E: ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
23	Jing P, Sa N and Xu W: miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 51:189–196. 2016.(In Chinese). PubMed/NCBI
24	Siney EJ, Holden A, Casselden E, Bulstrode H, Thomas GJ and Willaime-Morawek S: Metalloproteinases ADAM10 and ADAM17 mediate migration and differentiation in glioblastoma sphere-forming cells. Mol Neurobiol. Aug 19–2016.(Epub ahead of print). PubMed/NCBI
25	Zepeda-Nuño JS, Guerrero-Velázquez C, Del Toro-Arreola S, Vega-Magaña N, Ángeles-Sánchez J, Haramati J, Pereira-Suárez AL and Bueno-Topete MR: Expression of ADAM10, Fas, FasL and soluble FasL in patients with oral squamous cell carcinoma (OSCC) and their association with clinical-pathological parameters. Pathol Oncol Res. 23:345–353. 2017. View Article : Google Scholar : PubMed/NCBI
26	Detre S, Jotti Saclani G and Dowsett M: A ‘quickscore’ method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
27	Graham JK, Kunze E and Hammerstedt RH: Analysis of sperm cell viability, acrosomal integrity, and mitochondrial function using flow cytometry. Biol Reprod. 43:55–64. 1990. View Article : Google Scholar : PubMed/NCBI
28	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
29	Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
30	Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
31	Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008. View Article : Google Scholar : PubMed/NCBI
32	Reiss K and Saftig P: The ‘a disintegrin and metalloprotease’ (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol. 20:126–137. 2009. View Article : Google Scholar : PubMed/NCBI
33	Weber S and Saftig P: Ectodomain shedding and ADAMs in development. Development. 139:3693–3709. 2012. View Article : Google Scholar : PubMed/NCBI
34	Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P and Blobel CP: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 164:769–779. 2004. View Article : Google Scholar : PubMed/NCBI
35	van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R and Vooijs M: Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem. 284:31018–31027. 2009. View Article : Google Scholar : PubMed/NCBI
36	Liu S, Zhang W, Liu K, Ji B and Wang G: Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Mol Med Rep. 11:597–602. 2015.PubMed/NCBI